# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# 1) Submitter name, address, contact

Roche Diagnostics Corporation 9115 Hague Rd. Indianapolis, IN 46250 Office: (317) 521-7688 Fax: (317) 521-2324

Contact Person: Dimitris Demirtzoglou

Date Prepared: January 23, 2008

# Device name

# Proprietary name:

a. Control Set DAT I b. Control Set DAT II C. Control Set DAT III d. Control Set Amphetamine 1000 e. Control Set Amphetamine 500

# Regulatory information

Applicable to each of the devices.

Product Code: Product Code Name: Device Class: Classification panel: C.F.R section:

DIF   
Drug Mixture Control Materials   
Class I   
Clinical Toxicology   
862.3280 - Clinical Toxicology Control Material

# Predicate devices

We claim substantial equivalencc for each of the devices to the currently marketed TDM Control Set (K070200).

# Control Set DAT I

Control Set DAT I is prepared by the quantitative addition of drug or drug metabolite to drug-free human urine. Preservative and stabilizer are added to maintain product integrity.

Control Set DAT I contains a mixture of 10 different drugs. Drug concentrations in are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

<table><tr><td>Drug</td><td>Assay Cutoff</td><td>Target Concentration (ng/mL)</td></tr><tr><td></td><td>PreciNeg</td><td>PreciPos</td></tr><tr><td>Amphetamines (d- methamphetamine)</td><td>500 375</td><td>625</td></tr><tr><td>Barbiturates (secobarbital)</td><td>200 150</td><td>250</td></tr><tr><td>Benzodiazepines (nordiazepam)</td><td>300 225</td><td>375</td></tr><tr><td>Cannabinoids (∆9 THC- COOH)</td><td>50</td><td>37.5 62.5</td></tr><tr><td>Cocaine (benzoylecgonine)</td><td>150 113</td><td>188</td></tr><tr><td>Methadone (dl-methadone)</td><td>300 225</td><td>375</td></tr><tr><td>Methaqualone (methaqualone)</td><td>300 225</td><td>375</td></tr><tr><td>Opiates (d-morphine)</td><td>2000 1500</td><td>2500</td></tr><tr><td>PCP (phencyclidine)</td><td>25 18.8</td><td>31.3</td></tr><tr><td>Propoxyphene (propoxyphene)</td><td>300 225</td><td>375</td></tr></table>

# Control Set DAT II

Control Set DAT II is prepared by the quantitative addition of drug or drug metabolite to drug-free human urine. Preservative and stabilizer are added to maintain product integrity.

Control Set DAT II contains a mixture of 4 different drugs. Drug concentrations in Control Set DAT II are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

<table><tr><td>Assay Drug Cutoff</td><td>Target Concentration (ng/mL)</td></tr><tr><td></td><td>PreciNeg PreciPos</td></tr><tr><td>Amphetamines (d- 300 methamphetamine)</td><td>225 375</td></tr><tr><td>Benzodiazepines 100 (nordiazepam)</td><td>75 125</td></tr><tr><td>Cannabinoids (∆9 THC- 20 COOH)</td><td>15 25</td></tr><tr><td>Opiates (d-morphine) 300</td><td>225 375</td></tr></table>

# Control Set DAT III

Control Set DAT III is prepared by the quantitative addition of drug or drug metabolite to drug-free human urine. Preservative and stabilizer are added to maintain product integrity.

Control Set DAT III contains a mixture of 4 different drugs. Drug concentrations in Control Set DAT II are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

<table><tr><td>Drug</td><td>Assay Cutoff</td><td>Target Concentration (ng/mL)</td><td></td></tr><tr><td></td><td></td><td>PreciNeg</td><td>PreciPos</td></tr><tr><td>Amphetamines (d- methamphetamine)</td><td>1000</td><td>750</td><td>1250</td></tr><tr><td>Benzodiazepines (nordiazepam)</td><td>200</td><td>150</td><td>250</td></tr><tr><td>Cannabinoids (Δ9 THC- COOH)</td><td>100</td><td>75</td><td>125</td></tr><tr><td>Cocaine (benzoylecgonine)</td><td>300</td><td>225</td><td>375</td></tr></table>

# Control Set Amphetamine 1000

Control Set Amphetamine 1000 is prepared by the quantitative addition of damphetamine to drug-free human urine. Preservative is added to maintain product integrity.

Drug concentrations in Control Set Amphetamine 1000 are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

<table><tr><td>Drug</td><td>Assay Cutoff</td><td>Target Concentration (ng/mL)</td></tr><tr><td></td><td></td><td>PreciNeg PreciPos</td></tr><tr><td>Amphetamines (d-</td><td>1000</td><td>750 1250</td></tr></table>

# Control Set Amphetamine 500

Control Set Amphetamine 500 is prepared by the quantitative addition of damphetamine to drug-free human urine. Preservative is added to maintain product integrity.

Drug concentrations in Control Set Amphetamine 500 are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

<table><tr><td>Drug</td><td>Assay Cutoff</td><td colspan="2">Target Concentration (ng/mL)</td></tr><tr><td></td><td></td><td>PreciNeg</td><td>PreciPos</td></tr><tr><td>Amphetamines (d-</td><td>500</td><td>375</td><td>625</td></tr></table>

# Control Set DAT I

The Control Set DAT I is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers.

This product cannot be used with the Roche Abuscreen OnLine assay for Amphetamines or the COBAS INTEGRA Amphetamines cobas c pack (AMPS). Refer to the package insert or method sheet for information regarding the controls appropriate for use with these assays.

# Control Set DAT II

The Control Set DAT II is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers.

This product cannot be used with the Roche Abuscreen OnLine assay for Amphetamines or the COBAS INTEGRA Amphetamines cobas c pack (AMPS). Refer to the package insert or method sheet for information regarding the controls appropriate for use with these assays.

# Control Set DAT III

The Control Set DAT III is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers.

This product cannot be used with the Roche Abuscreen OnLine assay for Amphetamines or the COBAS INTEGRA Amphetamines cobas c pack (AMPS). Refer to the package insert or method sheet for information regarding the controls appropriate for use with these assays.

# Control Set Amphetamine 1000

The Control Set Amphetamine 1000 is for use as an assayed control with the Roche Abuscreen OnLine assay for Amphetamines and the COBAS INTEGRA Amphetamines cobas c pack (AMPS) for the qualitative and semiquantitative determination of amphetamines in human urine on automated clinical chemistry analyzers.

6.) Intended Use (continued)

# Control Set Amphetamine 500

The Control Set Amphetamine 500 is for use as an assayed control with the Roche Abuscreen OnLine assay for Amphetamines and the COBAS INTEGRA Amphetamines cobas c pack (AMPS) for the qualitative and semiquantitative determination of amphetamines in human urine on automated clinical chemistry analyzers.

# .) Comparison to the Predicate Device

Below the similarities and differences between the Control Set DAT I, Control Set DAT II, Control Set DAT III, Control Set Amphetamine 1000, Control Set Amphetamine 500, and its predicate device TDM Control Set (K070200) are presented.

Continued on next page

7.) Comparison to the Predicate Device (continued)   

<table><tr><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Control Set DAT I</td><td rowspan=1 colspan=1>TDM Control Set</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Control Set DAT I is for use as an assayedcontrol in the Roche test system for the qualitativeand semiquantitative determination of drugs ofabuse in human urine on automated clinicalchemistry analyzers.This product cannot be used with the RocheAbuscreen OnLine assay for Amphetamines or theCOBAS INTEGRA Amphetamines cobas c pack(AMPS). Refer to the package insert or methodsheet for information regarding the controlsappropriate for use with these assays.</td><td rowspan=1 colspan=1>The TDM Control Set is for use in quality controlby monitoring accuracy and precision for thequantitative methods as specified in the valuesheet.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Amphetamines (d-methamphetamine)Barbiturates (secobarbital)Benzodiazepines (nordiazepam)Cannabinoids (∆9 THC-COOH)Cocaine (benzoylecgonine)Methadone (dl-methadone)Methaqualone (methaqualone)Opiates (d-morphine)PCP (phencyclidine)Propoxyphene (propoxyphene)</td><td rowspan=1 colspan=1>•  AcetaminophenAmikacin•  CarbamazepineDigoxinGentamicinLidocaineN-acetylprocainamidePhenobarbitalPhenytoinPrimidoneProcainamideQuinidineSalicylateTheophyllineTobramycinValproic acid•  Vancomycin.</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>USP Standards</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human urine based</td><td rowspan=1 colspan=1>Human serum based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr></table>

Gas Chromatography/Mass Spectrometry

7.) Comparison to the Predicate Device (continued)   

<table><tr><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Control Set DAT II</td><td rowspan=1 colspan=1>TDM Control Set</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Control Set DAT II is for use as an assayedcontrol in the Roche test system for the qualitativeand semiquantitative determination of drugs ofabuse in human urine on automated clinicalchemistry analyzers.This product cannot be used with the RocheAbuscreen OnLine assay for Amphetamines or theCOBAS INTEGRA Amphetamines cobas c pack(AMPS). Refer to the package insert or methodsheet for information regarding the controlsappropriate for use with these assays.</td><td rowspan=1 colspan=1>The TDM Control Set is for use in quality controlby monitoring accuracy and precision for thequantitative methods as specified in the valuesheet.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>•Amphetamines (d-methamphetamine)Benzodiazepines (nordiazepam) Cannabinoids (∆9 THC-COOH)Opiates (d-morphine)</td><td rowspan=1 colspan=1>•  Acetaminophen•   Amikacin.  Carbamazepine.  Digoxin•  GentamicinLidocaine•  N-acetylprocainamidePhenobarbitalPhenytoinPrimidoneProcainamideQuinidineSalicylateTheophyllineTobramycinValproic acid•  Vancomycin.</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>USP Standards</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human urine based</td><td rowspan=1 colspan=1>Human serum based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr></table>

'Gas Chromatography/Mass Spectrometry

.) Comparison to the Predicate Device (continued)   

<table><tr><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Control Set DAT III</td><td rowspan=1 colspan=1>TDM Control Set</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Control Set DAT III is for use as an assayedcontrol in the Roche test system for the qualitativeand semiquantitative determination of drugs ofabuse in human urine on automated clinicalchemistry analyzers.This product cannot be used with the RocheAbuscreen OnLine assay for Amphetamines or theCOBAS INTEGRA Amphetamines cobas c pack(AMPS). Refer to the package insert or methodsheet for information regarding the controlsappropriate for use with these assays.</td><td rowspan=1 colspan=1>The TDM Control Set is for use in quality controlby monitoring accuracy and precision for thequantitative methods as specified in the valuesheet.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>•  Amphetamines (d-methamphetamine)Benzodiazepines (nordiazepam)Cannabinoids (Δ9 THC-COOH)Cocaine (benzoylecgonine)</td><td rowspan=1 colspan=1>.  AcetaminophenAmikacinCarbamazepineDigoxin.  GentamicinLidocaine.  N-acetylprocainamidePhenobarbital•  PhenytoinPrimidone.  ProcainamideQuinidine•  SalicylateTheophylline.  Tobramycin•  Valproic acid• Vancomycin.</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>GCMS</td><td rowspan=1 colspan=1>USP Standards</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human urine based</td><td rowspan=1 colspan=1>Human serum based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr></table>

Gas Chromatography/Mass Spectrometry

7.) Comparison to the Predicate Device (continued)   

<table><tr><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Control Set Amphetamine 1000</td><td rowspan=1 colspan=1>TDM Control Set</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Control Set Amphetamine 1000 is for use asan assayed control with the Roche AbuscreenOnLine assay for Amphetamines and the COBASINTEGRA Amphetamines cobas c pack (AMPS)for the qualitative and semiquantitativedetermination of amphetamines in human urine onautomated clinical chemistry analyzers.</td><td rowspan=1 colspan=1>The TDM Control Set is for use in quality controlby monitoring accuracy and precision for thequantitative methods as specified in the valuesheet.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Amphetamines (d-amphetamine)</td><td rowspan=1 colspan=1>•  Acetaminophen:  Amikacin•  Carbamazepine•  Digoxin•   Gentamicin•  LidocaineN-acetylprocainamidePhenobarbitalPhenytoin.  PrimidoneProcainamide•  Quinidine.  Salicylate•  Theophylline.  Tobramycin.   Valproic acid•  Vancomycin.</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>USP Standards</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human urine based</td><td rowspan=1 colspan=1>Human serum based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr></table>

Gas Chromatography/Mass Spectrometry

7.) Comparison to the Predicate Device (continued)   

<table><tr><td rowspan=1 colspan=2>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=2>Control Set Amphetamine 500</td><td rowspan=1 colspan=1>TDM Control Set</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=2>The Control Set Amphetamine 500 is for use as anassayed control with the Roche Abuscreen OnLineassay for Amphetamines and the COBASINTEGRA Amphetamines cobas c pack (AMPS)for the qualitative and semiquantitativedetermination of amphetamines in human urine onautomated clinical chemistry analyzers.</td><td rowspan=1 colspan=1>The TDM Control Set is for use in quality controlby monitoring accuracy and precision for thequantitative methods as specified in the valuesheet.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=2> Amphetamines (d-amphetamine)</td><td rowspan=1 colspan=1>•  Acetaminophen.   Amikacin.  Carbamazepine.  Digoxin.  GentamicinLidocaineN-acetylprocainamidePhenobarbitalPhenytoin.  PrimidoneProcainamide•  Quinidine.   Salicylate.  TheophyllineTobramycin.  Valproic acid• Vancomycin.</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=2>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>USP Standards</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=2>Human urine based</td><td rowspan=1 colspan=1>Human serum based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=2>2</td><td rowspan=1 colspan=1>3</td></tr></table>

Gas Chromatography/Mass Spectrometry

# MAR 25 2008

Roche Diagnostics Corp. c/o Mr. Dimitris Demirtzoglou Regulatory Affairs Consultant 9115 Hague Road, P.0. Box 50416 Indianapolis, IN 46250

Re: k080183 Trade Name: Control Set Dat I, Control Set Dat II, Control Set Dat III, Control Set Amphetamine 1000, Control Set Amphetamine 500 Regulation Number: 21 CFR 862.3280 Regulation Name: Clinical toxicology control material Regulatory Class: Class I, reserved Product Codes: DIF Dated: January 23, 2008 Received: January 25, 2008

Dear Mr. Demirtzoglou:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter willallow you to begin marketing your device as described in your Section 510(k) premarket notification.The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

# Indication for Use

510(k) Number (if known): k080183

# Device Name: Control Set DAT I, Control Set DAT II, Control Set DAT III, Control Set Amphetamine 1000, Control Set Amphetamine 500

Indication For Use:

The Control Set DAT I is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers as indicated in the System Information.

The Control Set DAT II is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers as indicated in the System Information.

The Control Set DAT II is for use as an assayed control in the Roche test system for the qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers as indicated in the System Information.

None of these above named products can be used with the Roche Abuscreen OnLine assay for Amphetamines or the COBAS INTEGRA Amphetamines cobas c pack (AMPS). The package insert or method sheet for information regarding the controls has appropriate instructions for use with these assays.

The Control Set Amphetamine 1000 is for use as an assayed control with the Roche Abuscreen OnLine assay for Amphetamines and the COBAS INTEGRA Amphetamines cobas c pack (AMPS) for the qualitative and semiquantitative determination of amphetamines in human urine on automated clinical chemistry analyzers.

The Control Set Amphetamine 500 is for use as an assayed control with the Roche Abuscreen OnLine assay for Amphetamines and the COBAS INTEGRA Amphetamines cobas c pack (AMPS) for the qualitative and semiquantitative determination of amphetamines in human urine on automated clinical chemistry analyzers.

Prescription Use _X And/Or Over the Counter Use (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concrrence f CDRH, Office f In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/d82dbf9e9831ee8022ef7aa816e59670f58cbb3c1525e153126cea58a24b8f01.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k)K080183